Blood pressure response to oral calcium in persons with mild to moderate hypertension: A randomized, double-blind, placebo-controlled, crossover trial

D. A. McCarron, Cynthia Morris

Research output: Contribution to journalArticle

236 Citations (Scopus)

Abstract

The blood pressure response of 48 hypertensive persons and 32 normotensive persons to elemental calcium (as the carbonate or citrate salt), 1000 mg/d for 8 weeks, was assessed in a randomized, double-blind, placebo-controlled, crossover trial. Compared with placebo, Ca2+ significantly lowered supine systolic blood pressure by 3.8 mm Hg, standing systolic blood pressure by 5.6 mm Hg (p <0.02), and supine diastolic blood pressure by 2.3 mm Hg (p <0.05) in hypertensive persons. The response in normotensive persons differed significantly from that in hypertensives (p <0.03) as their blood pressure was unchanged. Twenty-one (44%) hypertensive and 6 (19%) normotensive persons achieved a reduction in standing systolic arterial pressure of 10 mm Hg or greater. Reported adverse effects were similar between calcium and placebo phases and did not necessitate withdrawal of any patient from the trial. Treatment with 1000 mg/d of oral Ca2+ for 8 weeks represents a safe, well-tolerated, nonpharmacologic intervention that lowers blood pressure in selected patients with mild to moderate hypertension.

Original languageEnglish (US)
Pages (from-to)825-831
Number of pages7
JournalAnnals of Internal Medicine
Volume103
Issue number6 I
StatePublished - 1985

Fingerprint

Cross-Over Studies
Placebos
Blood Pressure
Hypertension
Calcium
Calcium Citrate
Calcium Carbonate
Arterial Pressure
Salts

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{c6be85d48c0f4a869da05a4f1abb9baa,
title = "Blood pressure response to oral calcium in persons with mild to moderate hypertension: A randomized, double-blind, placebo-controlled, crossover trial",
abstract = "The blood pressure response of 48 hypertensive persons and 32 normotensive persons to elemental calcium (as the carbonate or citrate salt), 1000 mg/d for 8 weeks, was assessed in a randomized, double-blind, placebo-controlled, crossover trial. Compared with placebo, Ca2+ significantly lowered supine systolic blood pressure by 3.8 mm Hg, standing systolic blood pressure by 5.6 mm Hg (p <0.02), and supine diastolic blood pressure by 2.3 mm Hg (p <0.05) in hypertensive persons. The response in normotensive persons differed significantly from that in hypertensives (p <0.03) as their blood pressure was unchanged. Twenty-one (44{\%}) hypertensive and 6 (19{\%}) normotensive persons achieved a reduction in standing systolic arterial pressure of 10 mm Hg or greater. Reported adverse effects were similar between calcium and placebo phases and did not necessitate withdrawal of any patient from the trial. Treatment with 1000 mg/d of oral Ca2+ for 8 weeks represents a safe, well-tolerated, nonpharmacologic intervention that lowers blood pressure in selected patients with mild to moderate hypertension.",
author = "McCarron, {D. A.} and Cynthia Morris",
year = "1985",
language = "English (US)",
volume = "103",
pages = "825--831",
journal = "Annals of Internal Medicine",
issn = "0003-4819",
publisher = "American College of Physicians",
number = "6 I",

}

TY - JOUR

T1 - Blood pressure response to oral calcium in persons with mild to moderate hypertension

T2 - A randomized, double-blind, placebo-controlled, crossover trial

AU - McCarron, D. A.

AU - Morris, Cynthia

PY - 1985

Y1 - 1985

N2 - The blood pressure response of 48 hypertensive persons and 32 normotensive persons to elemental calcium (as the carbonate or citrate salt), 1000 mg/d for 8 weeks, was assessed in a randomized, double-blind, placebo-controlled, crossover trial. Compared with placebo, Ca2+ significantly lowered supine systolic blood pressure by 3.8 mm Hg, standing systolic blood pressure by 5.6 mm Hg (p <0.02), and supine diastolic blood pressure by 2.3 mm Hg (p <0.05) in hypertensive persons. The response in normotensive persons differed significantly from that in hypertensives (p <0.03) as their blood pressure was unchanged. Twenty-one (44%) hypertensive and 6 (19%) normotensive persons achieved a reduction in standing systolic arterial pressure of 10 mm Hg or greater. Reported adverse effects were similar between calcium and placebo phases and did not necessitate withdrawal of any patient from the trial. Treatment with 1000 mg/d of oral Ca2+ for 8 weeks represents a safe, well-tolerated, nonpharmacologic intervention that lowers blood pressure in selected patients with mild to moderate hypertension.

AB - The blood pressure response of 48 hypertensive persons and 32 normotensive persons to elemental calcium (as the carbonate or citrate salt), 1000 mg/d for 8 weeks, was assessed in a randomized, double-blind, placebo-controlled, crossover trial. Compared with placebo, Ca2+ significantly lowered supine systolic blood pressure by 3.8 mm Hg, standing systolic blood pressure by 5.6 mm Hg (p <0.02), and supine diastolic blood pressure by 2.3 mm Hg (p <0.05) in hypertensive persons. The response in normotensive persons differed significantly from that in hypertensives (p <0.03) as their blood pressure was unchanged. Twenty-one (44%) hypertensive and 6 (19%) normotensive persons achieved a reduction in standing systolic arterial pressure of 10 mm Hg or greater. Reported adverse effects were similar between calcium and placebo phases and did not necessitate withdrawal of any patient from the trial. Treatment with 1000 mg/d of oral Ca2+ for 8 weeks represents a safe, well-tolerated, nonpharmacologic intervention that lowers blood pressure in selected patients with mild to moderate hypertension.

UR - http://www.scopus.com/inward/record.url?scp=0022358621&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022358621&partnerID=8YFLogxK

M3 - Article

C2 - 3904559

AN - SCOPUS:0022358621

VL - 103

SP - 825

EP - 831

JO - Annals of Internal Medicine

JF - Annals of Internal Medicine

SN - 0003-4819

IS - 6 I

ER -